eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Epilepsy
Interventions
DRUG

Lacosamide

"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."

Trial Locations (54)

Unknown

110, Huntsville

004, Phoenix

001, Fresno

008, Orange

030, Oxnard

108, Sacramento

025, Bradenton

015, Ocala

049, Panama City

114, Port Charlotte

012, Sarasota

014, Tampa

003, Wellington

123, Louisville

006, Hammond

112, Waldorf

129, Golden Valley

023, Springfield

088, Missoula

020, Camden

131, Greensboro

002, Akron

027, Canton

022, Columbus

005, Dayton

013, Oklahoma City

028, Lubbock

017, Salt Lake City

139, Madison

024, Milwaukee

075, Chatswood

079, Parkville

036, Rousse

037, Sofia

080, Sofia

081, Sofia

082, Sofia

059, Aarhus

087, Copenhagen

042, Angers

040, Limoges

046, Paris

065, Bielefeld

066, Hamburg

068, Tübingen

096, Bucharest

099, Bucharest

097, Lasi

038, Târgu Mureş

095, Târgu Mureş

051, Manresa

053, Oviedo

050, Seville

102, Gothenburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT01484977 - eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam | Biotech Hunter | Biotech Hunter